An examination of semantic performance in mild cognitive impairment progressors and nonprogressors

Emilie Delage1, Isabelle Rouleau1, Marc-Antoine Akzam-Ouellette1

  • 1Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal.

Neuropsychology
|February 15, 2024
PubMed
Abstract

Insights

Individuals with mild cognitive impairment (MCI) who show semantic deficits are at higher risk for Alzheimer's disease (AD) progression. Early identification of semantic impairment in MCI may predict future decline toward AD.

Area of Science:

  • Neuroscience
  • Gerontology
  • Cognitive Psychology

Background:

  • Mild cognitive impairment (MCI) is a significant risk factor for Alzheimer's disease (AD), with approximately 50% of individuals progressing within five years.
  • Understanding predictors of MCI progression is crucial for early intervention and disease management.

Purpose of the Study:

  • To compare the semantic performance of individuals with MCI who progress to AD (MCI-p) versus those who remain stable (MCI-np).
  • To investigate whether baseline semantic deficits predict future cognitive decline and progression to Alzheimer's disease.

Main Methods:

  • Analysis of 56 participants (aged 65-89) from the Consortium for Early Identification of Alzheimer's Disease-Quebec study.
  • Categorization of participants into MCI progressors (n=18) and non-progressors (n=38) over a 2-year period.
  • Assessment of initial semantic and nonsemantic cognitive performance using ANCOVA and longitudinal cognitive decline using repeated measures ANOVA.

Main Results:

  • MCI progressors demonstrated significantly poorer baseline performance on semantic tests (category fluency, object decision) compared to MCI non-progressors.
  • MCI progressors also showed deficits in executive functions (cognitive flexibility) but not episodic memory at baseline.
  • While semantic test progression rates did not differ, MCI progressors exhibited steeper declines in global cognition, episodic memory, and processing speed at follow-up.

Conclusions:

  • Semantic memory impairment, particularly when co-occurring with episodic memory deficits, is associated with an increased risk of progression from MCI to Alzheimer's disease.
  • These findings highlight the potential of semantic performance as an early indicator for Alzheimer's disease risk in individuals with MCI.

Related Concept Videos

Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
109
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
125
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
48